Cabozantinib (XL184) for Medullary Thyroid Cancer (EXAMINER Trial)
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Exelixis
No Placebo Group
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.
Eligibility Criteria
Treatment Details
2Treatment groups
Experimental Treatment
Group I: Cabozantinib (XL184) 60 mgExperimental Treatment2 Interventions
Cabozantinib (XL184) 60 mg as tablets and placebo capsules administered orally once a day.
Group II: Cabozantinib (XL184) 140 mgExperimental Treatment2 Interventions
Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
Find a clinic near you
Research locations nearbySelect from list below to view details:
NCT01896479Toronto, Canada
NCT01896479Québec, Canada
Loading ...
Who is running the clinical trial?
ExelixisLead Sponsor